Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Solid Tumors 2Neoplasm Metastasis 2Disease Progression 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00675012 2014-05-30

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

AGC Biologics S.p.A.

Phase 2 Completed
24 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡